Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancer

Barreto, InêsFigueiredo, SaraTonin, FernandaVilariça, Ana SofiaHasmucrai, DirendraAlves, Paula2024-04-022024-04-022023-10Barreto I, Figueiredo S, Tonin FS, Vilariça AS, Hasmucrai D, Alves P. Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancer. Port J Card Thorac Vasc Surg. 2023;30(3):9-11.http://hdl.handle.net/10400.21/17243Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), was recently introduced in several countries, including Portugal (reimbursement in 2021), as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating proto-oncogene epidermal growth factor receptor mutations (EGFRm), after showing significant efficacy and safety when used in patients with EGFR-T790M resistance mutations. However, despite advances in personalized target treatments in this field, challenges regarding patients’ journey (e.g., therapy selection criteria, EGFR-TKI optimal sequencing, treatment beyond second-line) still exist.engLung cancerNon-small-cell lung cancerEGFR mutationReal-world dataTyrosine kinase inhibitorsReal-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancerjournal article10.48729/pjctvs.381